Related Experiment Videos
Medical treatment of hyperprolactinemia
Hormone Research
|January 1, 1985
Summary
Medical treatment, primarily with dopamine agonists, is the standard for hyperprolactinemia, including prolactin-secreting tumors (prolactinomas). This approach effectively normalizes hormone levels and reduces tumor size.
Area of Science:
- Endocrinology
- Pharmacology
- Oncology
Background:
- Primary hyperprolactinemia is frequently caused by prolactinomas (micro- and macroadenomas) or idiopathic forms.
- Medical management is the primary treatment modality, favored for its efficacy in normalizing gonadal function and achieving tumor regression.
Purpose of the Study:
- To review current knowledge on medical treatment for hyperprolactinemia.
- To evaluate the efficacy of dopamine agonists in managing prolactinomas and related symptoms.
Main Methods:
- Retrospective analysis of 95 hyperprolactinemic patients treated with bromocriptine, metergoline, or CU 32085 between 1975 and 1983.
- Literature review of published series on hyperprolactinemia treatment.
Main Results:
- Dopamine agonists demonstrate significant prolactin-suppressing effects.
- Treatment influences gonadal and gonadotropic functions, leading to normalization.
- Antitumoral action results in tumor regression for both micro- and macroadenomas.
Conclusions:
- Medical therapy with dopamine agonists is effective for primary hyperprolactinemia and prolactinomas.
- Key considerations include side effects, treatment resistance, cure potential, tumor evolution, and contraception strategies.